Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: 7 | Mind Blowing Facts

3 Pharma Stock Buys for Last-Minute Year-End Profits

Growing healthcare spending and the use of cutting-edge technologies in the research and development of new drugs have put the pharmaceutical industry in a strong position for growth. With such constructive trends in mind, it's wise to buy fundamentally strong pharma stocks, Merck (MRK), Collegium (COLL) and Johnson & Johnson…

StockNews.com

Looking back on the challenges CEOs faced in 2023, from war to climate change to the A.I. boom

Looking ahead, 2024 likely will be filled with volatility, uncertainty, complexity, and ambiguity. That’s "VUCA" for you.

Fortune

Are These 3 Pharma Stocks Smart Buys for Bullish Investors?

The pharmaceutical industry's outlook looks promising, given robust healthcare spending worldwide and the rapid adoption of advanced digital technologies. Amid this, let’s find out if pharma stocks AbbVie (ABBV), Collegium Pharmaceutical (COLL), and Merck (MRK) are ideal buys now. Read on to know more….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Analyzing Pharma Stock Giants: JNJ, MRK, and ABBV

The pharmaceutical industry is set for long-term growth due to growing demand for quality drugs and therapies, an aging population, and the rise in lifestyle-related diseases. Now, let's explore the investment potential of industry giants Merck & Co (MRK), Johnson & Johnson (JNJ), and AbbVie (ABBV). Keep reading.

StockNews.com

Former Merck CEO Ken Frazier on the responsibility of CEOs to uphold principles despite politics

Plus: Frazier talks about the shareholders who trusted his vision enough to support him in his early days at the helm.

Fortune

The 3 Best Dow Jones Stocks to Invest in Now, According to Wall Street

Analysts are bullish on these three dividend-paying Dow stocks, with consensus "Strong Buy" ratings and more upside expected for this diverse set of blue chips.

Barchart

Ex-Merck CEO Ken Frazier says CEOs must uphold American values

Frazier was one of the first CEOs to publicly distance himself from President Donald Trump.

Fortune

Read news from The Economist, FT, and more,
with one subscription

COVID-19 treatments to enter the market with a hefty price tag

The COVID-19 treatments millions of have taken for free from the federal government will enter the private market next week with a hefty price tag

The Independent UK

3 Beaten-Down Dow Stocks to Buy in October

Dow Jones industrials, such as Nike, have pulled back significantly amid recent market turmoil, and now trade at a steep discount to consensus price target estimates.

Barchart

All in: Drugmakers say yes, they'll negotiate with Medicare on price, so reluctantly

Despite at least nine lawsuits against the government, all companies whose drugs are up for Medicare price negotiation will come to the bargaining table.

WEKU

Former Merck boss Ken Frazier wants CEOs to speak out

In a politicized world, the former Merck boss says CEOs should stand up and speak out. “Pick your spots.”

Fortune

How To Buy MRK For A 5% Discount, Or Achieve An 13% Annual Return

Yesterday, with Merck trading at $103.94, the November put option with a strike price of $100 was trading around $1.78. Traders selling this put would receive $178 in option premium.

Barchart

Amy Klobuchar on Biden's biggest win

Minnesota senator and anti-monopoly crusader explains how fixing Medicare's drug problem will help everybody

Salon

Managers say they support skills-based hiring. But many jobs still require 4-year degrees

Just over half of hiring managers say removing four-year degree requirements would positively impact their company's hiring practices, according to a OneTen report.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - US

Biden names 10 drugs for first negotiations to cut Medicare prices

Government claims prices could fall for 9m seniors but pharma companies claim cost-reduction program is unconstitutional

Fortune

Biden targets diabetes drug Jardiance, blood thinner Eliquis, and 8 others for controversial Medicare price talks. But any relief is still years away

The move is expected to cut costs in a few years for some patients but faces litigation from the drugmakers and heavy criticism from Republican lawmakers.

Chicago Sun-Times

Biden targets Jardiance, Eliquis and 8 other prescription drugs for Medicare price talks

President Joe Biden says for many Americans the cost of one drug can be “the difference between life and death” as his administration announces the first drugs that’ll be targeted for price negotiations in an effort to cut Medicare costs.

Roll Call

HHS lists first 10 drugs subject to Medicare price negotiation - Roll Call

The program is a major priority for Joe Biden, who ran for president in part on the promise to allow Medicare to negotiate drug prices.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

3M vs. Merck: Which Dow Dividend Stock is a Better Buy?

MMM and MRK have both underperformed markets in 2023, but offer healthy yields for value-minded investors. Which of these dividend stocks is a better pick for your portfolio right now?

The National (Scotland)

Jobs blow as science firm announces redundancies at Scottish plant

A SCOTTISH science and technology company has confirmed that "a small number" of employees are now facing redundancy.

The Conversation

'The dirty disease' – both smokers and non-smokers get lung cancer. They face stigma on top of illness

Earlier this year, federal health minister Mark Butler announced a new national Lung Cancer Screening Program. The first of its kind for lung cancer, the screening program will open initially to current and former smokers aged 50 to 70 years by July 2025. It aims to save lives by detecting…

TechRadar

LCD TVs are dead in the water and OLED is the future

LCD TV screens have stopped innovating, making it crystal clear OLED is the future.

Los Angeles Times

Michael Hiltzik: Merck says it's being 'coerced' into negotiating its drug prices with Medicare. That's nonsense

No one really expected the pharmaceutical industry to lie down and take it when Congress authorized Medicare to start negotiating prices of the prescription drugs it buys for enrollees.

Daily Record

Irvine healthcare firm plan £250,000 solar power project

North Ayrshire Council will decide on the application from Merck.

Salon

Merck sues to block lower Medicare costs

The company claims that the plan to allow Medicare to negotiate drug prices violates the First and Fifth Amendments

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.